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challenging intracellular pathogen, affecting 
11 to 21 million people every year, and 
128 000 to 161 000 deaths occur annually 
worldwide (WHO Report, Immunization, 
Vaccines and Biologicals, 11 September 
2018). Fluoroquinolones and third genera-
tion cephalosporins are commonly used as 
first line therapy for Salmonella infections; 
however, due to a significant increase in 
antimicrobial resistance[2,3] combined with 
recent reports of toxic and metabolic side 
effects resulting from the use of fluoro-
quinolones[4] (FDA Report, Drug Safety 
and Availability, 7 October 2018), there is 
an urgent need for alternative treatment 
options. One such option is the poly peptide 
antibacterial agent colistin, which was com-
monly employed in the 1950s for its potent 
activity against multidrug resistant (MDR) 
pathogens.[5] The use of colistin was aban-
doned due to its high level of neurotoxicity 
and nephrotoxicity, however the desperate 
need for new therapies has seen it re-emerge 
as a “last resort” treatment option for Gram-
negative MDR infections.[6,7] Its use is cur-
rently restricted to parenteral administration 
due to a low oral absorption and bioavailability, leading to consid-
erable research interest in optimization of oral drug activity with 
minimization of toxic effects.[8–11]
The emergence of nanotechnology-based medicines in recent 
years has proven to be an effective strategy for the treatment 
of infectious diseases.[12] The encapsulation of anti-infectives 
into nanocarrier systems may afford targeted delivery to the 
site of infection, by overcoming permeability limitations across 
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1. Introduction
Combating intracellular pathogens remains a considerable chal-
lenge, due to the ability of these infectious organisms to invade 
mammalian cells and even more take refuge in intracellular vac-
uoles. This problem is compounded by the poor permeability of 
some anti-infectives, which limits their use against such patho-
gens.[1] According to the WHO report, Salmonella is one such 
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cellular barriers and at the same time avoiding adverse off-target 
effects.[13,14] Encapsulating colistin into such a delivery system 
could therefore offer the possibility to administer a lower dose 
while still maintaining its antibacterial efficacy, and thereby 
minimize its systemic toxicity.[15] In addition, such a system 
would offer the opportunity to administer colistin orally, by pro-
tecting colistin from the harsh conditions of the gastrointestinal 
(GI) tract.[16] Nevertheless, only few studies have investigated 
the ability of colistin-loaded nanocarriers to be administered by 
alternative, noninjectable routes, with the main focus to date 
being on the treatment of pulmonary infections by inhalation/
pulmonary administration.[17–19] Liposomes are one of the most 
commonly utilized nanocarriers for the intracellular delivery 
of anti-infectives, providing the potential for improved cell pen-
etration and reduced anti-infective-associated toxicity.[13,20,21] The 
use of liposomes for oral administration faces many challenges, 
including the low pH of the stomach and the presence of diges-
tive enzymes, which may disrupt liposomal lipid bilayers and 
result in drug leakage.[22] Recent efforts have indicated the ability 
to formulate GI-stable liposomes by manipulating lipid composi-
tions or employing surface coatings; however, this is an area of 
ongoing research need.[23–25] The potential, further enhancement 
of the ability of nanoparticulate delivery systems to access and 
treat intracellular infections by functionalization of their surfaces 
with invasive moieties is also an area that warrants further inves-
tigation.[26] For instance, several strategies have been utilized to 
target and treat infected phagocytic cells. Mannose-conjugated 
nanogel could assist in antibiotic delivery into phagocytic cells 
via the mannose-receptors in macrophages.[27] In another study, 
extracellular vesicles of S. aureus were used to coat vancomycin-
loaded nanoparticles to target infected macrophages.[28] In the 
case of nonphagocytic cells, liposomes functionalized with invasin 
(InvA497), a membrane protein responsible for the invasive ability 
of Yersinia species of bacteria such as Y. pseudotuberculosis, have 
been shown to significantly improve the intracellular delivery of 
the poorly permeable antibiotic gentamicin into epithelial cells.[29] 
This strategy was adopted in order to mimic the pathway by 
which Y. pseudotuberculosis invades eukaryotic cells, through the 
interaction of bacterial InvA497 with cellular α5β1 integrin recep-
tors.[30] Many other bacteria possess a similar invasive strategy, for 
instance, Staphylococcus aureus possesses proteins that mediate its 
invasion into and ability to shelter within mammalian cells, such 
as fibrinogen binding protein (FnBP) and extracellular adherence 
protein (Eap). Eap is a secreted protein composed of composed 
of 4 to 6 EAP domains (≈97 amino acid residue domains that 
share homology with the C-terminal domain of bacterial superan-
tigens) joined by 9–11 amino acid residue linker regions, yielding 
in proteins with a total mass of about 50 to 70 kDa (depending 
on the S. aureus strain), joined by unknown 9–12 residue linker 
regions.[31] This excreted protein is able to bind to a number of 
host cell extracellular matrix components and to rebind to the sur-
face of S. aureus, and thereby promotes the invasion of S. aureus 
into cells.[32] This secretion and rebinding mechanism is similar 
to internalin (InlB) from Listeria monocytogenes, which can be 
associated with the bacteria but is also found in the supernatant 
in free form.[33] Moreover, it has been shown that mixing Eap with 
noninvasive bacteria or fluorescent beads promotes their inter-
nalization into eukaryotic cells.[34,35] Interestingly, despite its well-
documented ability to promote effective intracellular invasion of 
S. aureus and other bacteria, the exact mechanism by which Eap 
mediates bacterial internalization remains unclear;[36] to date, it 
has also not been investigated as a means for promoting intra-
cellular delivery of antibiotic-containing carrier systems. In the 
current work therefore, various liposomal formulations loaded 
with colistin were first investigated for their potential to act as oral 
delivery systems, by optimizing their stability in various biorele-
vant media. The most stable liposomes were then surface-func-
tionalized with Eap, and further characterized. The efficiency of 
colistin-loaded, Eap-functionalized liposomes to deliver colistin 
into epithelial cells was finally investigated, using HEp-2 and 
Caco-2 epithelial cells infected with the enteroinvasive bacterium 
Salmonella enterica.
2. Results and Discussion
2.1. Preparation and Characterization of Colistin-Loaded 
Liposomes
In order to prepare liposomes with the ability to withstand the 
harsh conditions of the gastrointestinal tract, saturated long 
carbon chain phospholipids were used.[37] In addition, 30 mol% 
of cholesterol was utilized, which has been shown to increase 
the integrity of vesicles by promoting alignment of phospho-
lipids alkyl chains, enabling a condensed packing of the lipid 
bilayer.[38,39] This results in either shifting or elimination of the 
phase transition of liposomes inducing more orderly behavior of 
lipid fatty acid chains.[39,40] Three different liposomal formulations 
consisting of 1,2-dipalmitoyl phosphatidylcholine/1,2-dipalmi-
toyl-sn-glycero-3-phospho-ethanolamine-N-(Glutaryl)/cholesterol 
(DPPC/DPPE-GA/CHOL), 1,2-distearoyl-sn-glycero-3-phospho-
choline/DPPE-GA/cholesterol (DSPC/DPPE-GA/CHOL), and 
DPPC/DSPC/DPPE-GA /CHOL were prepared, loaded with var-
ious colistin concentrations (1, 2, 3, 4, 5, and 10 mg mL−1), and 
characterized (Col-Lip-1, Col-Lip-2, and Col-Lip-3 respectively). 
The size of all liposome formulations was ≈200 nm, with all for-
mulations having a low polydispersity index and a negative sur-
face charge (Figure S1a–c, Supporting Information). Colistin was 
encapsulated with entrapment efficiencies (EE) ranging from 
10% to 60%, inversely proportional with colistin concentration 
(Figure S1d, Supporting Information), while loading capacities 
(LC) ranged from 20% to 80%, proportional to colistin concentra-
tions (Figure S1e, Supporting Information). This phenomenon can 
be explained by the ability of colistin to disturb liposomal formula-
tions, as a result of its positively charged nature; thus, an increase 
in colistin concentration may lead to progressive disruption of the 
liposomal structure and a reduced capacity for drug incorporation. 
In contrast, the proportional increase in LC may be explained by 
a progressive decrease in liposome yield with increasing colistin 
concentration. A similar effect was observed by Wallace et al. using 
lipid film hydration method as well as freeze drying technique.[41] 
The effect of colistin on artificial membrane models has also been 
investigated previously and has shown various effects ranging 
from increasing surface roughness to pore formation and leakage 
of contents.[42] Liposomes prepared using 4 mg mL-1 of colistin 
with ≈30% EE and 50% LC were employed for further studies 
since the EE and LC variations were minor between the three for-
mulations. Scanning (SEM) and Cryo-transmission (Cryo-TEM) 
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electron microscopy images of Col-Lip-1 containing 4 mg mL-1 
colistin (as a representative formulation) confirmed the presence 
of spherical particles of ≈200 nm in diameter, in line with the 
dynamic light scattering (DLS) results of Figure S1 in the Sup-
porting Information (Figure 1). However, further optimization 
of the formulation process was carried out including an increase 
of rotation speed during the lipid film hydration step, as well as 
the employment of a sonication step before liposome extrusion 
(Experimental Section), that yielded an increase of EE to over 55% 
and gave LC results of 50% (Table 1). Encapsulation of hydrophilic 
drugs into liposomes using lipid film hydration has been associ-
ated with low EE compared to other methods.[43,44] Wallace et al. 
have achieved 40% EE of colistin in 1,2-dioleoyl-sn-glycero-3-phos-
phocholine-based liposomes prepared with lipid hydration using 
5 mg mL−1 of colistin.[41] The EE obtained in this work, therefore, 
are comparable to the previous studies and considered reasonably 
high using such a method, which could be attributed potentially to 
the ability of colistin to incorporate into the lipid bilayer.[41,45]
Colistin-loaded liposomes were subjected to thermal char-
acterization using differential scanning calorimetry (DSC)[46] 
(Figure S2, Supporting Information). Incorporation of 30% 
cholesterol into the liposomes resulted in an abolishment of 
the phase transition of DPPC (41 °C) and DSPC (55 °C) in the 
determined range of 0 to 80 °C.[47,48] The loading of colistin into 
the liposomes did not affect the lipid bilayers in comparison to 
drug-free liposomes (data not shown).
2.2. Stability in Biorelevant Media
The prepared liposomal formulations are proposed as delivery 
systems to be used for oral administration. Therefore, those 
liposomes should withstand the harsh conditions of the gastro-
intestinal tract and thereby retain their encapsulated colistin, 
preventing its burst release and degradation. To assess the 
stability of liposomes within conditions characteristic of the 
environment within the gastrointestinal tract, various biorele-
vant media were employed. Fasted state simulated gastric fluid 
(FaSSGF) was used as a medium mimicking the composition 
of fluids in a fasted stomach. This medium is mainly character-
ized by a low pH (1.6) and presence of pepsin (0.1 mg mL−1), 
which is one of the main digestive enzymes in the GI tract.[49] 
Fasted state simulated intestinal fluid without enzymes 
(FaSSIF) or with enzymes (FaSSIF-Enz) were employed, as 
established media mimicking the composition of fluids in the 
upper small intestine in the absence of food[50,51] Moreover, 
to simulate the conditions in the small intestine after meal 
intake, fed state simulated intestinal fluid (FeSSIF) was used.[52] 
Liposomes were incubated within each medium at 37 °C for 
5 h, which is the estimated total time required for an orally 
administrated drug to be absorbed.[53] The amount of released 
colistin as well as its integrity were monitored hourly via high-
performance liquid chromatography (HPLC), and the colloidal 
parameters of liposomes were also measured.
Col-Lip-1 showed a burst release of colistin of ≈10% to 15% 
upon addition to FaSSGF, FaSSIF, and FaSSIF-Enz, following 
which less than 20% of colistin was observed to be released 
for the remainder of the 5 h incubation period. Incubation of 
Col-Lip-1 in PBS (control medium) did not show any release 
of colistin during the 5 h study period, while 58% of colistin 
was released from Col-Lip-1 incubated in FeSSIF (Figure 2a). 
Col-Lip-2 released less than 10% of total drug load in PBS, 
FaSSGF and FaSSIF, whereas 32% and 18% of colistin was 
released in FaSSIF-Enz and FeSSIF respectively over a 5 h 
period (Figure 2b). In contrast, Col-Lip-3 showed a release of 
5% in FaSSIF and a maximum of 20% in other media after the 
5 h (Figure 2c). The considerable release of colistin from Col-
Lip-1 in FeSSIF indicates a vulnerability of these liposomes 
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Figure 1. Representative images of Col-Lip-1 using a) scanning electron microscopy and b) Cryo-Transmission electron microscopy, showing unila-
mellar spherical shaped liposomes of 200 nm.
Table 1. Characteristics of liposomes loaded with 4 mg mL−1 colistin.
Formulation Molar ratio Size [nm] PDI ζ-Potential [mV] EE [%] LC [%]
Col-Lip-1 DPPC:DPPE-GA:CHOL 1:0.2:1 211.8 ± 1.7 0.05 ± 0.1 −21.0 ± 0.6 55.3 ± 5.2 49.8 ± 0.4
Col-Lip-2 DSPC:DPPE-GA:CHOL 1:0.2:1 201.3 ± 1.0 0.05 ± 0.1 −17.3 ± 0.3 61.7 ± 5.7 50.9 ± 0.7
Col-Lip-3 DPPC:DSPC:DPPE-GA:CHOL 1:1:0.2:1 202.7 ± 1.4 0.03 ± 0.1 −15.3 ± 1.2 59.3 ± 4.3 50.4 ± 0.3
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to high concentrations of bile salts and the presence of lipol-
ysis products, and therefore an inability to effectively retain 
colistin within the fed small intestine. Col-Lip-2 and Col-Lip-3 
showed a better stability in the GI-simulated media, which 
could be attributed to the presence of the longer chain phos-
pholipid DSPC in their lipid bilayers. These findings are in 
line with what has been reported previously, namely, that 
DSPC-containing liposomes are able to withstand the poten-
tially destabilizing effects of bile salts and enzymes.[54,55] With 
respect to the colloidal parameters, no notable changes were 
observed in liposomal size and polydispersity index (PDI) in 
all tested media for the three formulations, except in FaSSIF-
Enz, where the size increased to more than 600 nm and PDI 
to more than 0.4 (Figure 2d,e). However, in this particular 
case, the presence of protein (pancreatin) in the medium is 
likely to have interfered with the DLS measurements, as it 
has been demonstrated that the formation of protein–protein 
or protein–liposome aggregates (as well as protein corona) 
can significantly affect DLS results.[56] Thus, Cryo-TEM was 
employed for further investigation. Imaging of stability 
study samples in FaSSIF-Enz (liposomes diluted 1:10 in the 
medium) showed the presence of aggregates as well as intact 
spherical liposomes of ≈200 nm in diameter (Figure S3, Sup-
porting Information). In FeSSIF, the PDI increased in the 
three formulations despite the unchanged average size. This 
is due to the presence of bile salts and lipid micelles in this 
medium, which could be measured by DLS (≈70 nm). Other 
studies employing biorelevant media simulating human 
intestinal fluids have similarly demonstrated the presence 
of various colloidal assemblies in these media, ranging from 
ellipsoidal micelles to larger structures including vesicles, 
rods, and discs.[57–62] The ζ-potential of all liposomal formula-
tions was negative in all tested media; the magnitude of sur-
face charge varied from ≈−6 to −30 mV however, reflective of 
the different media compositions and their subsequent effects 
on liposome surface charge.[63] Further experiments were 
carried out using only Col-Lip-2 and Col-Lip-3 formulations, 
as these were more stable in terms of chemical and colloidal 
parameters in comparison to Col-Lip-1.
2.3. Functionalization of Colistin-Loaded Liposomes with Eap
In order to enhance the internalization of liposomes into 
epithelial cells, the bacteria-derived invasion protein Eap was 
investigated for its ability to promote liposome cellular uptake. 
Liposomes were functionalized with 40 µg mL−1 Eap either by 
covalent coupling, using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-
4-methylmorpholinium (DMTMM) as a cross-linker, or by 
physical adsorption to liposomal surfaces. The quantification of 
Eap associated with liposomal surfaces could not be performed 
by commonly used methods such as bicinchoninic acid or 
Bradford assays due to the interference of colistin, and there-
fore sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Adv. Healthcare Mater. 2019, 1900564
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Figure 2. Cumulative percentage of colistin released from liposomes a) Col-Lip-1, b) Col-Lip-2 and c) Col-Lip-3 in different biorelevant media: FaSSGF 
(square), FaSSIF (triangle), FaSSIF-Enz (diamond), FeSSIF (circle), and PBS (star) over 5 h. Stability study results d) size e) PDI and f) ζ-Potential 
of liposomal formulations Col-Lip-1, Col-Lip-2, and Col-Lip-3 after 5 h incubation in biorelevant media. Data are shown as mean ± SEM from three 
independent replicates (N = 3, n = 9).
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(SDS-PAGE) was used to quantify the functionalization effi-
ciency (FE). SDS-PAGE gels showed a distinct Eap band at 
55 kDa in both functionalized liposome samples and standards 
(Figure 3a). The efficiency of Eap functionalization of Col-Lip-3 
was significantly highly than that of Col-Lip-2, utilizing both 
physical adsorption (75% and 52% respectively) and covalent 
coupling methods (57% and 38% respectively) (Figure 3b). The 
high FE achieved by physical adsorption could be attributed to 
the considerable adhesive properties of Eap, via electrostatic 
interactions.[64] For further experiments, Col-Lip-3 functional-
ized with Eap via physical adsorption was employed, due to the 
high FE obtained in this case.
2.4. Uptake of Eap-Functionalized Liposomes in Epithelial Cells
Uptake studies were performed by addition of rhodamine-
labeled liposomes (red fluorescence) to two different epithelial 
cell lines: Caco-2 cells and HEp-2 cells. The percentage of fluo-
rescent cells (indicative of cells containing liposomes) was then 
determined using flow cytometry (FACS). Caco-2 cells were 
grown as a confluent monolayer until transepithelial electrical 
resistance (TEER) values reached >500 Ω cm2 (Figure S4, Sup-
porting Information) to resemble the barrier properties of the 
small intestinal epithelial layer.[65,66] Eap and colistin as well as 
liposomal lipid concentrations used in this study were not cyto-
toxic for either cell type (Figure S5, Supporting Information). 
Different concentrations of bound Eap (5, 10, and 20 µg mL−1) 
were applied on HEp-2 cells (1 and 2 h incubation) and Caco-2 
monolayers (2 and 4 h incubation). Uptake results showed 
that only 3% of nonfunctionalized Col-Lip-3 were taken up by 
HEp-2 cells (Figure 4a), whereas 20% of Caco-2 cells were posi-
tively labeled after 2 h (Figure 4c). This may point to a differ-
ence in HEp-2 and Caco-2 cell mechanisms of particle uptake, 
further addressed below. Upon the incubation of HEp-2 cells 
with Eap-functionalized liposomes, the percentage of positively 
labeled cells increased in a time- and concentration-dependent 
manner, reaching almost 100% using 10 and 20 µg mL−1of Eap 
after 2 h (Figure 4a,b). For Caco-2 cell monolayers, a 2 h incu-
bation with liposomes functionalized with 20 µg mL−1 of Eap 
resulted in 75% of cells being fluorescently labeled (45% when 
10 µg mL−1 Eap was employed for functionalization, and 12% 
with 5 µg mL−1 Eap) (Figure 4c). Therefore, cells were further 
incubated for 4 h with Eap-functionalized liposomes, which 
resulted in a significant increase in uptake, reaching almost 
100% when 20 µg mL−1 Eap was used for functionalization 
(Figure 4c,d).
In another approach to study the uptake of Eap-func-
tionalized liposomes, cells were incubated (HEp-2 cells: 
2 h, Caco-2 cells: 4 h) with liposomes, stained, and visualized 
using confocal microscopy. The two cell lines were incubated 
with liposomes for different incubation periods in order to 
reflect the time period required for optimal uptake, as seen in 
Figure 4. Similarly to the flow cytometry-based uptake results, 
only liposomes which had been functionalized with Eap were 
seen to be internalized into HEp-2 cells (visible as red cytosolic 
staining in Figure 5a, and Figures S6a, and S7a in Supporting 
Information). With respect to Caco-2 cells, Eap-functionalized 
liposomes were present in almost all visualized cells; however, 
nonfunctionalized liposomes could also be detected within a 
small number of cells (Figure 5b, and Figures S6b and S7b in 
Supporting Information). This observation also fits with the 
results obtained from flow cytometry analysis, indicating that, 
in contrast to HEp-2 cells (Figure 5a), Caco-2 cells are able 
to take up nonfunctionalized liposomes to a certain degree 
(Figure 5b).
In order to investigate this further, and to also probe the 
existence of any difference in the mechanism of uptake of 
Eap-functionalized liposomes, an uptake assay at 4 °C was 
performed with both cell types. At this temperature, Caco-2 
cells showed a significant decrease in the percentage of rho-
damine-labeled cells (14%) compared to the uptake at 37 °C. 
Interestingly, their uptake by HEp-2 cells was not affected at 
this temperature (Figure 6a,b). The temperature dependency of 
Caco-2 cells uptake points toward an energy-dependent mecha-
nism, which has been previously reported using different types 
Adv. Healthcare Mater. 2019, 1900564
Figure 3. a) SDS-PAGE gel of Eap standards (5, 10, 20, 30, 40, and 50 µg mL−1) as well as non-functionalized colistin liposomes (Col-Lip-2 and Col-
Lip-3), Eap-functionalized colistin liposomes via surface adsorption (EapCol-Lip-2 (ads) and EapCol-Lip-3 (ads)) or via covalent coupling (EapCol-Lip-2 
(cov) and EapCol-Lip-3 (cov)). b) Functionalization efficiency of liposomes functionalized with Eap via surface adsorption (‘Eap (ads)’, solid bars) 
and covalent coupling (‘Eap (cov)’, striped bars). Data are shown as mean ± SEM from three independent replicates (N = 3, n = 9). Significance was 
defined as **P < 0.01 and ***P < 0.001.
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of liposomes.[67,68] However, the uptake mechanism of Eap as 
mentioned earlier, is not yet well understood and more studies 
are needed to characterize the specific pathways involved in 
the binding and internalization of this protein.[36,69] There-
fore, an uptake experiment in Caco-2 cells was conducted 
using endocytosis inhibitors (Figure 6c). Results showed a 
decrease of the uptake percentage of ≈8% after using Cytocha-
lasin D as an inhibitor of actin polymerization and, therefore, 
inhibition of macropinocytosis.[70,71] Moreover, a decrease in 
uptake of ≈17% was observed when using either chlorproma-
zine as an inhibitor of clathrin-dependent endocytosis (which 
translocates clathrin from the cell surface to the intracellular 
compartment),[72,73] or MβCD + lovastatin as an inhibitor of 
clathrin-independent (and caveolae-independent) endocytosis 
mechanisms.[74] In addition, 40% of the uptake was inhibited 
in the presence of the caveolae-dependent endocytosis inhib-
itor “filipin III,” which acts as a sterol-binding agent that dis-
rupts caveolae and caveolae-like structures.[75,76] These results 
show that the internalization of Eap-functionalized liposomes 
by Caco-2 cells involves pathways which predominantly utilize 
caveolae-mediated endocytosis.
2.5. Impact of Eap-Functionalized Liposomes Containing 
Colistin on Infected Cells
Conventional liposomes typically composed of only phospho-
lipids and/or cholesterol carrying antibacterial agents have 
previously been shown to kill intracellular bacteria, mainly resi-
dent in phagocytic cells.[27,28,77–81] However, in nonphagocytic 
cells, it can be difficult to achieve such an effect in the absence 
of surface functionalization.[82–86] Therefore, the ability of the 
bioinspired Eap-functionalized liposomes to facilitate effec-
tive intracellular delivery of the poorly permeable anti-infective 
colistin was investigated. For this purpose, HEp-2 and Caco-2 
cells infected with the enteroinvasive bacterium S. enterica were 
employed. After initial optimization of the infection conditions 
(see Figure S8, Supporting Information), a multiplicity of infec-
tion (MOI) of 100 was used to infect cells for 1 h followed by 2 h 
of gentamicin treatment to kill any extracellular bacteria. Cells 
containing S. enterica were then treated as informed by FACS 
results for 2 h (HEp-2 cells) or 4 h (Caco-2 cells) with nonfunc-
tionalized or Eap-functionalized (20 µg mL−1 Eap) liposomes 
loaded with 30 µg mL−1 colistin. Unloaded liposomes and 
Adv. Healthcare Mater. 2019, 1900564
Figure 4. a) Percentages of rhodamine-positive HEp-2 cells (1 and 2 h) and b) the corresponding histogram plots, c) percentages of rhodamine-positive 
Caco-2 cells (2 and 4 h) and d) the corresponding histogram plots resulting from treatment of cells with non-functionalized liposomes (Col-Lip-3) and 
Col-Lip-3 functionalized with different Eap concentrations (5, 10 and 20 µg mL−1). Controls were the untreated cells. Data are shown as mean ± SEM 
from three independent replicates (N = 3, n = 9). Significance was defined as *P < 0.05, **P < 0.01 and ***P < 0.001.
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colistin (as a free drug, 30 µg mL−1) were here utilized as con-
trols. The choice of 30 µg mL−1 colistin concentration is based 
on 10 times the minimum inhibitory concentration (MIC) of 
colistin acting on S. enterica (Figure S9, Supporting Informa-
tion). Eap concentration was chosen after a dose response study 
performed with different concentrations of Eap, where the 
highest bacterial killing percentage was achieved by using 
20 µg mL−1 Eap in both cell types (Figure S10a,b, Supporting 
Information). The viability of HEp-2 and Caco-2 cells after 
infection and liposomal treatment was unchanged in com-
parison to noninfected/untreated cells (Figure S11, Supporting 
Information). In both S. enterica-infected HEp-2 and Caco-2 
Adv. Healthcare Mater. 2019, 1900564
Figure 5. Representative confocal images of a) HEp-2 cells (2 h), b) Caco-2 cells (4 h) of untreated cells (control), treated with non-functionalized 
colistin liposomes (Col-Lip-3) or Eap-functionalized colistin liposomes (EapCol-Lip-3) are shown. Cell membranes were stained with fluorescein-WGA 
(green), nuclei were stained with DAPI (blue), and rhodamine-labelled liposomes were visualized as red dotted particles (red).
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cells, treatment with the Eap-functionalized liposomes loaded 
with colistin was seen to significantly reduce the intracellular 
bacterial load by ≈32% and 30% respectively when compared 
to nonfunctionalized liposomes and free colistin (Figure 7). 
Moreover, treatment of S. enterica-infected HEp-2 cells or 
Caco-2 cells with different concentrations of Eap-functionalized 
liposomes containing colistin (colistin: 30, 50, 80, 100, 150, and 
200 µg mL−1) resulted in a concentration-dependent increase 
of the bacterial killing to reach a maximum of ≈60% and 40% 
respectively (Figure S10c,d, Supporting Information). Such a 
result demonstrates that Eap-functionalized liposomes are not 
only able to invade into epithelial cells, but also, when drug 
loaded, are able to release their payload inside cells in order to 
exert a pharmacological effect. Interestingly, nonfunctionalized 
Adv. Healthcare Mater. 2019, 1900564
Figure 7. Bacterial Killing percentages of Salmonella enterica in a) HEp-2 cells and b) Caco-2 cells after treatment with colistin (Col), empty liposomes 
(Lip-3), nonfunctionalized colistin liposomes (Col-Lip-3), and Eap-functionalized colistin liposomes (EapCol-Lip-3). In all cases a colistin concentration 
of 30 µg mL−1 was used (Col, Col-Lip-3 and EapCol-Lip-3) and an Eap concentration of 20 µg mL−1 was employed, where relevant (EapCol-Lip-3). Data 
are show as mean ± SEM from four independent replicates (N = 4, n = 12). Significance was defined as *P < 0.05 and **P < 0.01.
Figure 6. a) Percentages of rhodamine-positive HEp-2 cells and Caco-2 cells and b) the corresponding histogram plots resulting from treatment of cells 
with colistin-loaded liposomes functionalized with 20 µg mL−1 of Eap for 2 h at 37 °C (stripes) and 4 °C (solid). c) Effects of the different endocytosis 
inhibitors at 37 °C for 1 h; cytochalasin (Cyto D, 1 mg mL−1), chlorpromazine (CPZ, 10 µg mL−1), filipin III (1 µg mL−1), and methyl-β-cyclodextrin/
lovastatin (MβCD, 10 mmol L−1/1 µg mL−1), on the internalization of Eap-functionalized liposomes into Caco-2 cells (4 h, 20 µg mL−1 Eap was used 
for functionalization). Control were cells treated with Eap-functionalized liposomes without any inhibitors. Data are shown as mean ± SEM from three 
independent replicates (N = 3, n = 9). Significance was defined as **P < 0.01 and ***P < 0.001.
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liposomes loaded with colistin were able to induce only a low 
degree of bacterial killing in Caco-2 cells, reducing the infection 
load by 6%. Those liposomes were, although to a lower extent, 
able to enter cells and release colistin, which is in agreement 
with uptake results obtained by FACS and confocal laser scan-
ning microscopy (CLSM) (Figures 4 and 5). In a previous study, 
we could show similar intracellular antibacterial effect with 
another bacteriomimetic delivery system, namely, InvA497-
functionalized liposomes loaded with gentamicin,[29] However, 
after an oral administration this system is only able to target 
cells with apically expressed α5β1 integrin receptors, i.e., mainly 
microfold cells in the small intestine.[87] Eap, on the other hand, 
is able to interact with different cell types,[88] and, therefore, 
offers a broader targeting of the gastrointestinal epithelium.
3. Conclusion
A liposomal carrier encapsulating the hydrophilic polypep-
tide anti-infective, colistin, was first formulated to withstand 
the acidic and enzymatic environment of the GI tract. This 
was achieved by combining long chain phospholipids DPPC 
and DSPC with cholesterol, which increased the stability of 
liposomes. Subsequently surface functionalization with a bac-
terial-derived protein, Eap, could be shown to mediate the inter-
nalization of these liposomes into epithelial cells. By facilitating 
intracellularly delivery of their anti-infective cargo, i.e., colistin, 
which is normally unable to permeate across cellular mem-
branes, a substantial killing of the enteroinvasive bacterium 
S. enterica in epithelial cells was achieved. The Eap-mediated 
internalization pathway—which has not been well character-
ized to date—was shown to occur in either an energy dependent 
or independent manner, varying with cell type. Uptake via an 
energy-dependent mechanism was in itself determined to 
involve several different pathways. While this study provides 
valuable insight into the little-known uptake mechanism of Eap, 
further investigation is required to dissect the mechanisms by 
which Eap binds to and is internalized into cells. The current 
study also showed, for the first time, the potential of Eap as an 
invasive moiety for intracellular drug delivery. The employed, 
bioinspired delivery strategy gives a new hope for neglected or 
problematic antibacterial agents like colistin to be used orally 
at moderate doses and thereby reducing otherwise prohibitive 
adverse effects.
4. Experimental Section
Materials: DPPC (Lipoid E PC) and DSPC were kindly provided from 
Lipoid GmbH (Ludwigshafen, Germany). 1,2-Dipalmitoyl-sn-glycero-3-
phospho-ethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium 
salt) (Rh-DPPE) and DPPE-GA (DPPE-GA) were purchased from Avanti 
Polar Lipids (Alabama, USA). Colistin sulfate (>90% purity) was 
obtained from Adipogen GmbH (Hamburg, Germany). Cholesterol and 
ammonium thiocyanate (NH4SCN) were purchased from Sigma Aldrich 
(Steinheim, Germany). Ferric 3-chloride-hexahydrate (FeCl3·6H2O) was 
obtained from Merck KGaA, Darmstadt, Germany, Biochrom, Germany. 
All other chemicals and solvents used were at least of analytical grade.
Preparation and Characterization of Colistin-loaded Liposomes: 
Liposomes were prepared using the lipid film hydration method.[89] 
Briefly, different liposomal formulations according to Table 1 were 
prepared by dissolving phospholipids and cholesterol in a mixture of 
chloroform:methanol (2:1). Rh-DPPE (10 µg mL−1) was additionally 
added to fluorescently label liposomes. The organic solvents were 
evaporated using a rotary evaporator (Buchi, Switzerland) with a 
heating bath heated to 70 °C, at 200 mbar for 1 h. After the formation 
of a lipid film, different concentrations of colistin solution in phosphate-
buffered saline (PBS) were used for hydrating the lipid film (1, 2, 
3, 4, 5, and 10 mg mL−1), achieved by continual rotation at 50 °C for 
1 h. The resulting vesicles were sonicated for 3 min with a sonication 
bath and extruded 10 times through 200 nm pore size polycarbonate 
membranes (Polycarbonate track-Etch Membrane, Sartorius Germany) 
at 70 °C, using an extruder (LiposoFast L-50, Avestin, Germany). The 
mean diameter and PDI of liposomes were measured by DLS, while 
the ζ-potential of liposomes was determined by laser doppler micro-
electrophoresis. All physical characterizations were performed using a 
Zetasizer Nano ZS (Malvern Instruments, United Kingdom).
Liposomes Imaging: SEM and Cryo-TEM were used to visualize 
liposomal morphologies. For SEM imaging, colistin-loaded liposomes 
were centrifuged twice at 7000 g for 10 min and pellets were 
re-suspended in water to remove any traces of PBS. Samples were then 
diluted 1:20, and a volume of 10 µL was mounted on aluminum stubs, 
using double-sided adhesive carbon tape and copper grids (Micro to 
Nano, Netherlands). After drying, samples were sputter-coated with thin 
gold film using a Quorum Q150R ES sputter-coater (Gala Instrumente 
GmbH, Germany). SEM imaging was performed using Zeiss EVO HD15 
(Zeiss, Germany) under an acceleration voltage of 5 kV, and images were 
processed with SmartSEM software. Cryo-TEM imaging was conducted 
by placing a (3 µL) droplet of the liposomes solution onto a S147-4 holey 
carbon film (Plano, Germany) before blotting to a thin liquid film for 2 s. 
Afterward samples were plunged at T = 108 K into liquid ethane using 
a Gatan (Pleasonton, USA) CP3 Cryo plunge system and visualized at 
T = 100 K using a JEOL (Akishima, Japan) JEM-2100 LaB6 TEM operating 
at an accelerating voltage of 200 kV at low-dose conditions.
Entrapment Efficiency and Loading Capacity: Liposomes were 
purified by centrifugal ultrafiltration using Centrisart tubes fitted with a 
300 000 molecular weight cut-off membrane (Sartorius AG, Germany). 
Centrifugation was carried out at 3270 g and 4 °C for 30 min, and was 
repeated twice to ensure the complete removal of unencapsulated drug. 
An HPLC method was then used for quantification of entrapped colistin 
as previously described with some modifications.[90] Briefly, a Dionex 
Ultimate 3000 HPLC system (Thermo Scientific, Germany) composed 
of a pump, a degassing system, an autosampler, a column oven, and a 
diode array detector was used. A LiChrospher 100 RP-18 (125 × 4 mm, 
5 µm) column (Merck KGaA, Germany) was employed. As colistin 
consists of two components colistin A and B, separation of colistin A 
and B peaks was achieved using a linear gradient of acetonitrile: (0.1%) 
trifluoroacetic acid (20:80 to 50:50) over a 10 min period. A flow rate of 
1 mL min−1 was applied with an injection volume of 100 µL. The oven 
temperature was set to 30 °C during the analysis. The retention times of 
colistin A and B were 6.15 and 6.99 min respectively, and the area under 
the curve (AUC) of both peaks was used for colistin quantification. The 
entrapment efficiency[91] (EE) and the loading capacity[92] (LC) were 
calculated according to the following equations
EE(%)
quantified amount of colistin
initial amount of colistin
100= ×  (1)
LC(%)
quantified amount of colistin
quantified amounts of phospholipids cholesterol colistin
100=
+ +
×  (2)
Phospholipids amount was determined using a colorimetric assay 
previously described by Stewart.[93] The assay reagent was prepared by 
dissolving FeCl3·6H2O (27.03 g) and NH4SCN (30.4 g) in water (1 L). 
Phospholipids standards were prepared in chloroform (0.1 mg mL−1). 
Liposomes were dissolved in chloroform (1:20) and then an equal 
volume of the assay reagent was added to the samples and standards. 
The amount of phospholipids in liposomes was determined by 
measuring the absorbance at 485 nm. The amount of cholesterol 
Adv. Healthcare Mater. 2019, 1900564
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incorporated in liposomes was quantified using HPLC.[94] The mobile 
phase consisted of acetonitrile:methanol (70:30 v/v) with a flow 
rate of 2 mL min−1. Cholesterol peak was detected at a wavelength 
of 210 nm after 15 min analysis time. Standards were prepared 
from a stock solution (200 µg mL−1) of cholesterol in (50:50, v/v) 
acetonitrile:methanol/ethyl acetate (1/1 v/v). Whereas, samples were 
prepared by dissolving liposomes (400 µL) in acetonitrile:methanol/
ethyl acetate mixture (1 mL).
Stability Studies in Biorelevant Media: Stability studies of the prepared 
liposomes were conducted in fasted state simulated gastric fluid, fasted 
stated simulated intestinal fluid, and FASSIF containing additional 
enzymes . Fed state simulated intestinal fluid was also employed. Media 
were prepared as described in Table 2. Liposomes were diluted 1:10 in 
different media and incubated at 37 °C for 5 h. Samples were collected 
every hour, purified and analyzed for size, PDI, zeta potential, and 
colistin content as described above.
Eap Purification: Eap was obtained from S. aureus strain Newman[95] as 
previously described.[96] Briefly, purification of Eap was carried by cation 
exchange chromatography on a Mono S 5/50 GL column (GE Healthcare, 
Germany) using a fast-performance liquid chromatography system 
(Bio-Rad, Germany). Eap-positive fractions were then detected by SDS-
PAGE using Coomassie blue staining and pooled to a final concentration 
of 2 mg mL−1. After sterilization through 200 nm filters (Merck KGaA, 
Germany), purified Eap was stored at −80 °C until further use.
Liposome Functionalization: Liposomes were functionalized with 
Eap either covalently (cov) using DMTMM (Sigma Aldrich, Germany) 
as a coupling reagent or physically via adsorption of Eap to liposomal 
surfaces (ads). For surface adsorption, liposomes were incubated directly 
with 40 µg mL−1 Eap under stirring (180 rpm) at room temperature for 
1 h. For the covalent coupling, carboxylic groups on liposomes were first 
activated using DMTMM (0.5 mmol L−1) at room temperature under 
stirring (180 rpm) for 2 h. Afterward, Eap (40 µg mL−1) was added to 
the surface-activated liposomes under stirring at room temperature 
for 1 h. The excess of Eap was removed using Centrisart tubes (as 
described above for purification of unentrapped colistin). The amount 
of Eap functionalized on liposomes was quantified using SDS-PAGE.[97] 
Eap standards (5, 10, 20, 30, 40, and 50 µg mL−1), nonfunctionalized 
liposomes, and Eap-functionalized liposomes were loaded onto the 
polyacrylamide gel and the electrophoresis was conducted for 40 min 
at 120 mV. Page Blue Protein staining (Bio-Rad, Germany) was used to 
stain the gel for 1 h under a gentle shaking. The gel was then rinsed with 
water and distained in a water bath overnight under a gentle shaking 
at room temperature. Gel DocTM EZ imager (Bio-Rad, Germany) was 
used for imaging the gel and ImageJ software to process the images. 
The functionalization efficiency (FE) was calculated 
using the following equation[29]
FE(%)
quantified amount of Eap
initial amount of Eap
100= ×  (3)
Cell Culture: Human adenocarcinoma cells 
of clone HTB-37 (Caco-2) and human laryngeal 
carcinoma cells (HEp-2) were purchased from 
American Type Culture Collection (ATCC, Rockville, 
MD). Caco-2 cells were cultured in 75 cm2 culture 
flasks in Dulbecco’s Modified Eagle Medium 
(DMEM, Gibco, Germany) supplemented with 10% 
fetal calf serum (FCS) (Lonza, Cologne, Germany) 
and 1% nonessential amino acids (NEAA, 
Gibco, Germany). HEp-2 cells were cultured in 
75 cm2 culture flasks in Roswell Park Memorial 
Institute medium (RPMI 1640) (Life Technologies, 
Paisley, UK) supplemented with 10% FCS. Cells 
were incubated at 37 °C, 5% CO2, and 95% 
relative humidity in an incubator CB 210 (Binder, 
Germany) and medium was changed every third 
day. Cells were harvested for experiments using 
trypsin (0.1%) and EDTA solution (0.02%, Sigma, 
Steinheim, Germany), and subcultured once a week to maintain the 
cultures. Cells from passages 30–40 (Caco-2 cells) and 20–32 (HEp-2 
cells) were used for all of the experiments.
Uptake Studies: HEp-2 cells were grown on 24-well plates (2 × 104 
cells per well) for 72 h, while Caco-2 cells were seeded on Transwell 
inserts (Corning Incorporated, Acton, MA) with a pore size of 0.4 µm 
(6 × 104 cells per insert) and allowed to form a differentiated monolayer. 
Transepithelial electrical resistance (TEER) was measured with an 
epithelial volt/ohm meter equipped with a Chopstick electrode (World 
Precision Instruments, USA) over time to monitor the integrity of 
the Caco-2 cell monolayer, and experiments were performed using 
monolayers with TEER values ≥500 Ω cm2. All cells were washed twice with 
PBS and then incubated with different concentrations (5, 10, 20 µg mL−1) 
of Eap-functionalized or nonfunctionalized liposomes, or medium 
(negative control) at 37 °C and 5% CO2, for 2 or 4 h. Afterward, cells 
were washed to remove liposomes, harvested, and re-suspended in 
PBS for flow cytometry analysis (LSRFortessa, BD Bioscience, USA). A 
minimum of 10 000 live cells were analyzed from forward versus side 
scatter (FSC versus SSC) gating. The percentage of rhodamine positive 
cells after taking up Rh-DPPE-containing liposomes was determined 
with FlowJo 7.6.5 software (FlowJo LLC, USA) using PE channel.
Cell Imaging: HEp-2 cells were seeded at a density of 4 × 104 cells per 
well on 24-well imaging plates and allowed to grow to 90% confluence. 
Caco-2 cells were cultivated as a monolayer on glass coverslips (for 
imaging) and Transwells (for TEER measurements) in 24-well plates 
and only used for the experiment when TEER values ≥ 500 Ω cm2 were 
reached. Cells were treated with liposomes functionalized with Eap 
(20 µg mL−1), or nonfunctionalized liposomes. Cells were washed with 
PBS, and then incubated with fluorescein-labeled wheat germ agglutinin 
(10 µg mL−1) (Vector Laboratories, USA) to stain the cell membrane for 
15 min at 37 °C and 5% CO2. Afterward, cells were washed with PBS 
and fixed with 3% paraformaldehyde for 30 min at room temperature. 
Nuclei were stained with 4′,6-Diamidin-2-phenylindol (DAPI, 1 µg mL−1) 
(Life Technologies, Germany) for 15 min and coverslips were mounted 
on slides using mounting medium (Thermo, Germany). A confocal 
laser-scanning microscope (CLSM Leica TCS SP8, Leica Microsystems, 
Germany) was used to visualize cells. Images were taken with a 25× 
water immersion objective (1024 × 1024 resolution) and processed 
using LAS X software (LAS X 1.8.013370, Leica Microsystems, Germany).
Uptake Mechanism: HEp-2 cells were seeded on 24-well plates 
and Caco-2 cells were seeded on Transwell inserts with TEER values 
≥500 Ω cm2 and incubated with either nonfunctionalized liposomes or 
Eap-functionalized liposomes at 4 °C for 2 h. Cells were washed with PBS, 
trypsinized, and then analyzed with flow cytometry. Afterward Caco-2 cells 
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Table 2. Biorelevant media composition.
Composition FaSSGFa)[49] FaSSIFb)/FaSSIF-Enzc)[50,51] FeSSIFd)[52]
Sodium taurocholate [mmol L−1] 0.08 3 15
Phosphatidylcholine [mmol L−1] 0.02 0.75 3.75
Pepsin [mg mL−1] 0.1 – –
Sodium chloride [mmol L−1] 34.2 105.9 65.1
Oleic acid [mmol L−1] – – 5
Monoolein [mmol L−1] – – 2.5
Maleic acid [mmol L−1] – – 100
Sodium azide [mmol L−1] – – 3
Lipase (Pancreatin) [USP mL−1] – 600e) –
Ad. Deionized water [mL] 1000 500 50
pH 1.6 6.5 6.5
a)FaSSGF (Fasted state simulated gastric fluid); b)FaSSIF (Fasted state simulated intestinal fluid); c)FaSSIF-
Enz (Fasted state simulated intestinal fluid containing enzymes); d)FeSSIF (Fed state simulated intestinal 
fluid); e)Pancreatin was only added in FaSSIF-Enz.
www.advancedsciencenews.com www.advhealthmat.de
1900564 (11 of 12) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
were subjected to a following experiment using endocytosis inhibitors. 
Cells grown on Transwells were washed with PBS, then different inhibitors 
were added separately to both Transwell compartments, chlorpromazine 
(10 µg mL−1), cytochalasin D (1 mg mL−1), filipin III (1 µg mL−1), and 
methyl-β-cyclodextrin/ lovastatin (10 mmol L−1/1 µg mL−1) in Hank’s 
Balanced Salt Solution (HBSS).[98,99] After 1 h of incubation at 37° C, 
liposomes were applied to the apical compartment in the presence of 
inhibitors and cells were then incubated for another 2 h at 37° C. Afterward, 
cells were washed, trypsinized, and analyzed with flow cytometry.
Antibacterial Efficacy Assays: Salmonella enterica subsp. enterica 
(Leibniz-Institute DSMZ, Braunschweig, Germany) was cultured in 
nutrient broth medium (NB) overnight at 37 °C, and then diluted 1:5 
in fresh NB and incubated for a further 2.5 h in order to allow bacteria 
to reach the exponential growth phase. HEp-2/Caco-2 cells were then 
incubated with Salmonella (MOI of 100) at 37 °C, 5% CO2, and 95% 
humidity for 1 h, in order to allow for bacterial invasion. Cells were then 
washed with PBS and incubated with gentamicin solution (50 µg mL−1) 
for 2 h to kill any extracellular bacteria. Afterward, cells were treated 
with either Eap-functionalized liposomes (7, 12, 20, or 40 µg mL−1 of 
Eap), nonfunctionalized liposomes containing colistin, or colistin as free 
drug (colistin dose in all cases = 30 µg mL−1), in order to investigate 
the impact of Eap concentration on system efficacy; or, with liposomes 
functionalized with 20 µg mL−1 Eap, containing various concentrations 
of colistin (30, 50, 80, 100, 150, 200 µg mL−1) in order to investigate the 
occurrence of a colistin dose-response relationship. The final antibacterial 
assay was performed using liposomes containing 30 µg mL−1  
colistin and functionalized with 20 µg mL−1 Eap. In all cases, 
formulations were incubated with infected cells for a period of 2 h 
(HEp-2 cells) or 4 h (Caco-2 cells). Afterward, cells were washed and 
lysed with ice-cold water. Lysates were plated on nutrient agar plates and 
incubated at 37 °C for 18 h. Colonies were counted, and the percentage 
of killing was calculated by normalizing the number of colonies in the 
treated samples to the ones of untreated control.
Statistical Analysis: All the experiments were performed at least in 
triplicates and expressed as mean ± SEM. No data preprocessing was 
performed. One-way-ANOVA followed by a post hoc test was used 
to calculate statistical significance using OriginPro software (with 
*P < 0.05,**P < 0.01, and ***P < 0.001 considered as significant).
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from the author.
Acknowledgements
The authors thank Dr. Chiara De Rossi for her support with analytics 
and confocal imaging, as well as Petra Koenig and Jana Westhues for 
their support in cell culture. J.E. and M.B. were supported by SFB 1027 
grant B2.
Conflict of Interest
The authors declare no conflict of interest.
Keywords
bacterial invasion, bacteriomimetic nanocarriers, Eap, extracellular 
adherence proteins, simulated intestinal fluids, Staphylococcus aureus
Received: May 3, 2019
Revised: June 27, 2019
Published online: 
[1] R. K. Ernst, T. Guina, S. I. Miller, J. Infect. Dis. 1999, 179, S326.
[2] C. D. Britto, V. K. Wong, G. Dougan, A. J. Pollard, PLOS Neglected 
Trop. Dis. 2018, 12, e0006779.
[3] A. Karkey, G. Thwaites, S. Baker, Curr. Opin. Gastroenterol. 2018, 34, 
25.
[4] B. A. Golomb, H. J. Koslik, A. J. Redd, BMJ Case Rep. 2015, 2015.
[5] J. Li, R. J. Nation, J. D. Turnidge, R. W. Milne, K. Coulthard, 
C. R. Rayner, D. L. Paterson, Lancet Infect. Dis. 2006, 6, 589.
[6] S. Biswas, J.-M. Brunel, J.-C. Dubus, G. M. Reynaudt, J.-M. Rolain, 
Expert Rev. Anti-Infect. Ther. 2012, 10, 917.
[7] M. E. Falagas, S. K. Kasiakou, Clin. Infect. Dis. 2005, 40, 1333.
[8] I. Karaiskos, L. Friberg, K. Pontikis, K. Ioannidis, V. Tsagkari, 
L. Galani, E. Kostakou, F. Baziaka, C. Paskalis, A. Koutsoukou, 
H. Giamarellou, Antimicrob. Agents Chemother. 2015, 59, 7240.
[9] R. L. Nation, S. M. Garonzik, J. Li, V. Thamlikitkul, 
E. J. Giamarellos-Bourboulis, D. L. Paterson, J. D. Turnidge, 
A. Forrest, P. F. Silveira, Clin. Infect. Dis. 2016, 62, 552.
[10] G. G. Rao, N. S. Ly, C. E. Haas, S. Garonzik, A. Forrest, J. B. Bulitta, 
P. A. Kelchlin, P. N. Holden, R. L. Nation, J. Li, B. T. Tsuji, Antimi-
crob. Agents Chemother. 2014, 58, 1381.
[11] F. Shahbazi, Expert Rev. Clin. Pharmacol. 2015, 8, 423.
[12] R. Singh, J. W. Lillard, Exp. Mol. Pathol. 2009, 86, 215.
[13] N. Abed, P. Couvreur, Int. J. Antimicrob. Agents 2014, 43, 485.
[14] H. Pinto-Alphandary, A. Andremont, P. Couvreur, Int. J. Antimicrob. 
Agents 2000, 13, 155.
[15] D. Wang, L. Kong, J. Wang, X. He, X. Li, Y. Xiao, PDA J. Pharm. Sci. 
Technol. 2009, 63, 159.
[16] J. Li, R. L. Nation, R. W. Milne, J. D. Turnidge, K. Coulthard, Int. J. 
Antimicrob. Agents 2005, 25, 11.
[17] E. Sans-Serramitjana, E. Fusté, B. Martínez-Garriga, A. Merlos, 
M. Pastor, J. L. Pedraz, A. Esquisabel, D. Bachiller, T. Vinuesa, 
M. Viñas, J. Cystic Fibrosis 2016, 15, 611.
[18] M. Pastor, M. Moreno-Sastre, A. Esquisabel, E. Sans, M. Viñas, 
D. Bachiller, V. J. Asensio, A. D. Pozo, E. Gainza, J. L. Pedraz, Int. J. 
Pharm. 2014, 477, 485.
[19] Y. Li, C. Tang, E. Zhang, L. Yang, Pharm. Dev. Technol. 2017, 22, 436.
[20] Z. Drulis-Kawa, A. Dorotkiewicz-Jach, Int. J. Pharm. 2010, 387, 187.
[21] R. Schiffelers, G. Storm, I. Bakker-Woudenberg, J. Antimicrob. 
Chemother. 2001, 48, 333.
[22] W. Wu, Y. Lu, J. Qi, Ther. Delivery 2015, 6, 1239.
[23] H. He, Y. Lu, J. Qi, Q. Zhu, Z. Chen, W. Wu, Acta Pharm. Sin. B 
2019, 9, 36.
[24] H. T. H. Vu, S. M. Hook, S. D. Siqueira, A. Müllertz, T. Rades, 
A. McDowell, Int. J. Pharm. 2018, 548, 82.
[25] M. Daeihamed, S. Dadashzadeh, A. Haeri, M. F. Akhlaghi, Curr. 
Drug Delivery 2017, 14, 289.
[26] R. Mout, D. F. Moyano, S. Rana, V. M. Rotello, Chem. Soc. Rev. 
2012, 41, 2539.
[27] M.-H. Xiong, Y.-J. Li, Y. Bao, X.-Z. Yang, B. Hu, J. Wang, Adv. Mater. 
2012, 24, 6175.
[28] F. Gao, L. Xu, B. Yang, F. Fan, L. Yang, ACS Infect. Dis. 2019, 5, 218.
[29] S. Menina, H. I. Labouta, R. Geyer, T. Krause, S. Gordon, P. Dersch, 
C.-M. Lehr, RSC Adv. 2016, 6, 41622.
[30] P. Dersch, R. R. Isberg, EMBO J. 1999, 18, 1199.
[31] M. Hammel, D. Neˇmecˇek, J. A. Keightley, G. J. Thomas, 
B. V. Geisbrecht, Protein Sci. 2007, 16, 2605.
[32] A. Haggar, M. Hussain, H. Lönnies, M. Herrmann, 
A. Norrby-Teglund, J. I. Flock, Infect. Immun. 2003, 71, 2310.
[33] M. Bonazzi, M. Lecuit, P. Cossart, Cold Spring Harbor Perspect. Biol. 
2009, 1, a003087.
[34] M. Flock, J.-I. Flock, J. Bacteriol. 2001, 183, 3999.
[35] I. Joost, S. Jacob, O. Utermöhlen, U. Schubert, J. M. Patti, 
M.-F. Ong, J. Gross, C. Justinger, J. H. Renno, K. T. Preissner, 
M. Bischoff, M. Herrmann, FEMS Immunol. Med. Microbiol. 2011, 
62, 23.
Adv. Healthcare Mater. 2019, 1900564
www.advancedsciencenews.com www.advhealthmat.de
1900564 (12 of 12) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Healthcare Mater. 2019, 1900564
[36] J. Josse, F. Laurent, A. Diot, F. Microbiol. 2017, 8, 2433.
[37] J. Parmentier, N. Thomas, A. Müllertz, G. Fricker, T. Rades, Int. J. 
Pharm. 2012, 437, 253.
[38] T. Róg, FEBS Lett. 2001, 502, 68.
[39] M.-L. Briuglia, C. Rotella, A. McFarlane, D. A. Lamprou, Drug 
Delivery Transl. Res. 2015, 5, 231.
[40] S.-C. Lee, K.-E. Lee, J.-J. Kim, S.-H. Lim, J. Liposome Res. 2005, 15, 157.
[41] S. J. Wallace, J. Li, R. L. Nation, R. J. Prankerd, B. J. Boyd, J. Pharm. 
Sci. 2012, 101, 3347.
[42] Y. F. Mohamed, H. M. Abou-Shleib, A. M. Khalil, N. M. El-Guink, 
M. A. El-Nakeeb, Braz. J. Microbiol. 2016, 47, 381.
[43] K. Muppidi, A. S. Pumerantz, J. Wang, G. Betageri, ISRN Pharm. 
2012, 2012, 636743.
[44] J.-P. Colletier, B. Chaize, M. Winterhalter, D. Fournier, BMC 
Biotechnol. 2002, 2, 9.
[45] C. Mestresa, M. A. Alsinaa, M. A. Busquetsa, I. Murányib, F. Reigc, 
Int. J. Pharm. 1998, 160, 99.
[46] H. Bunjes, T. Unruh, Adv. Drug Delivery Rev. 2007, 59, 379.
[47] K. J. Fritzsching, J. Kim, G. P. Holland, Bioch. Biophys. Acta 2013, 
1828, 1889.
[48] D. A. Mannock, R. N. A. H. Lewis, R. N. McElhaney, Biophys. J. 
2006, 91, 3327.
[49] M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, C. Reppas, Eur. 
J. Pharm. Biopharm. 2005, 60, 413.
[50] E. Jantratid, N. Janssen, C. Reppas, J. B. Dressman, Pharm. Res. 
2008, 25, 1663.
[51] P. Sassene, K. Kleberg, H. D. Williams, J.-C. Bakala-N’Goma, 
F. Carrière, M. Calderone, V. Jannin, A. Igonin, A. Partheil, 
D. Marchaud, E. Jule, J. Vertommen, M. Maio, R. Blundell, 
H. Benameur, C. J. H. Porter, C. W. Pouton, A. Müllertz, AAPS J. 
2014, 16, 1344.
[52] L. H. Nielsen, S. Gordon, R. Holm, A. Selen, T. Rades, A. Müllertz, 
Eur. J. Pharm. Biopharm. 2013, 85, 942.
[53] Y. Y. Lee, A. Erdogan, S. C. S. Rao, J. Neurogastroenterol. Motil. 2014, 
20, 265.
[54] M. Kokkona, P. Kallinteri, D. Fatouros, S. G. Antimisiaris, Eur. J. 
Pharm. Sci. 2000, 9, 245.
[55] R. N. Rowland, J. F. Woodley, Biochim. Biophys. Acta 1980, 620, 400.
[56] B. Lorber, F. Fischer, M. Bailly, H. Roy, D. Kern, Biochem. Mol. Biol. 
Educ. 2012, 40, 372.
[57] R. P. Hjelm, C. Schteingart, A. S. Hofmann, D. S. Sivia, J. Phys. 
Chem. 1995, 99, 16395.
[58] T. Nawroth, P. Buch, K. Buch, P. Langguth, R. Schweins, Mol. Phar-
maceutics 2011, 8, 2162.
[59] A. Müllertz, C. Reppas, D. Psachoulias, M. Vertzoni, D. G. Fatouros, 
J Pharm. Pharmacol. 2015, 67, 486.
[60] D. Riethorst, P. Baatsen, C. Remijn, A. Mitra, J. Tack, J. Brouwers, 
P. Augustijns, Mol. Pharmaceutics 2016, 13, 3484.
[61] P. A. Elvang, A. H. Hinna, J. Brouwers, B. Hens, P. Augustijns, 
M. Brandl, J. Pharm. Sci. 2016, 105, 2832.
[62] A. J. Clulow, A. Parrow, A. Hawley, J. Khan, A. C. Pham, P. Larsson, 
C. A. S. Bergström, B. J. Boyd, J. Phys. Chem. B 2017, 121, 10869.
[63] A. Amici, G. Caracciolo, L. Digiacomo, V. Gambini, C. Marchini, 
M. Tilio, A. L. Capriotti, V. Colapicchioni, R. Matassa, G. Familiari, 
S. Palchetti, D. Pozzi, M. Mahmoudi, A. Laganà, RSC Adv. 2017, 7, 
1137.
[64] J. Eisenbeis, M. Saffarzadeh, H. Peisker, P. Jung, N. Thewes, 
K. T. Preissner, M. Herrmann, V. Molle, B. V. Geisbrecht, K. Jacobs, 
M. Bischoff, Front. Cell. Infect. Microbiol. 2018, 8, 235.
[65] I. D. Angelis, L. Turco, Curr. Protoc. Toxicol. 2011, 47, 20.6.1.
[66] F. Leonard, E.-M. Collnot, C.-M. Lehr, Mol. Pharmaceutics 2010, 7, 2103.
[67] Y. Kono, H. Jinzai, Y. Kotera, T. Fujita, Biol. Pharm. Bull. 2017, 40, 2166.
[68] X. Li, D. Chen, C. Le, C. Zhu, Y. Gan, L. Hovgaard, M. Yang, Int. J. 
Nanomed. 2011, 6, 3151.
[69] S. Bur, K. T. Preissner, M. Herrmann, M. Bischoff, J. Invest. 
Dermatol. 2013, 133, 2004.
[70] S. Gold, P. Monaghan, P. Mertens, T. Jackson, PLoS One 2010, 5, 
e11360.
[71] R. Kanlaya, K. Sintiprungrat, S. Chaiyarit, V. Thongboonkerd, Cell 
Biochem. Biophys. 2013, 67, 1171.
[72] F. Chen, L. Zhu, Y. Zhang, D. Kumar, G. Cao, X. Hu, Z. Liang, 
S. Kuang, R. Xue, C. Gong, Sci. Rep. 2018, 8, 7268.
[73] D. Dutta, J. G. Donaldson, Cell. Logist. 2012, 2, 203.
[74] S. K. Rodal, G. Skretting, O. Garred, F. Vilhardt, B. van Deurs, 
K. Sandvig, Mol. Biol. Cell 1999, 10, 961.
[75] J. Rejman, A. Bragonzi, M. Conese, Mol. Ther. 2005, 12, 468.
[76] J. E. Schnitzer, P. Oh, E. Pinney, J. Allard, J. Cell Biol. 1994, 127, 1217.
[77] P. Lutwyche, C. Cordeiro, D. J. Wiseman, M. St-Louis, M. Uh, 
M. J. Hope, M. S. Webb, B. B. Finlay, Antimicrob. Agents Chemother. 
1998, 42, 2511.
[78] M. Magallanes, J. Dijkstra, J. Fierer, Antimicrob. Agents Chemother. 
1993, 37, 2293.
[79] S. Majumdar, D. Flasher, D. S. Friend, P. Nassos, D. Yajko, 
W. K. Hadley, N. Duzgunes, Antimicrob. Agents Chemother. 1992, 36, 
2808.
[80] Y. K. Oh, D. E. Nix, R. M. Straubinger, Antimicrob. Agents Chem-
other. 1995, 39, 2104.
[81] J. P. Wong, H. Yang, K. L. Blasetti, C. J. G. Schnell, J. Conley, 
L. N. Schofield, J. Controlled Release 2003, 92, 265.
[82] N. A. Atchison, W. Fan, K. K. Papas, B. J. Hering, M. Tsapatsis, 
E. Kokkoli, Langmuir 2010, 26, 14081.
[83] M. B. Hansen, E. van Gaal, I. Minten, G. Storm, J. C. M. van Hest, 
D. W. P. Löwik, J. Controlled Release 2012, 164, 87.
[84] H. I. Labouta, S. Menina, A. Kochut, S. Gordon, R. Geyer, P. Dersch, 
C. M. Lehr, J. Controlled Release 2015, 220, 414.
[85] W. Fan, D. Xia, Q. Zhu, L. Hu, Y. Gan, Drug Discovery Today 2016, 
21, 856.
[86] A. Goes, G. Fuhrmann, ACS Infect. Dis. 2018, 4, 881.
[87] M. A. Clark, B. H. Hirst, M. A. Jepson, Infect. Immun. 1998, 66, 1237.
[88] N. Harraghy, M. Hussain, A. Haggar, T. Chavakis, B. Sinha, 
M. Herrmann, J.-I. Flock, Microbiology 2003, 149, 2701.
[89] A. D. Bangham, M. M. Standish, J. C. Watkins, J. Mol. Biol. 1965, 
13, 238.
[90] L. Bai, Z. Ma, G. Yang, J. Yang, J. Cheng, J. Chromatogr. Sep. Tech. 
2011, 2, 1000105.
[91] Z. Zhang, S. S. Feng, Biomaterials 2006, 27, 4025.
[92] S. Papadimitriou, J. Controlled Release 2009, 138, 177.
[93] J. C. Stewart, Anal. Biochem. 1980, 104, 10.
[94] N. Simonzadeh, J. Chromatogr. Sci. 2009, 47, 304.
[95] E. S. Duthie, L. L. Lorenz, J. Gen. Microbiol. 1952, 6, 95.
[96] A. N. Athanasopoulos, M. Economopoulou, V. V. Orlova, A. Sobke, 
D. Schneider, H. Weber, H. G. Augustin, S. A. Eming, U. Schubert, 
T. Linn, P. P. Nawroth, M. Hussain, H.-P. Hammes, M. Herrmann, 
K. T. Preissner, T. Chavakis, Blood 2006, 107, 2720.
[97] A. B. Nowakowski, W. J. Wobig, D. H. Petering, Metallomics 2014, 
6, 1068.
[98] L. M. Alexander, S. Pernagallo, A. Livigni, R. M. Sánchez-Martín, 
J. M. Brickman, M. Bradley, Mol. BioSyst. 2010, 6, 399.
[99] J. Zhang, X. Zhu, Y. Jin, W. Shan, Y. Huang, Mol. Pharmaceutics 
2014, 11, 1520.
